Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.

@article{Nishiguchi2001PreventionOH,
  title={Prevention of hepatocellular carcinoma in patients with chronic active hepatitis C and cirrhosis.},
  author={Shuhei Nishiguchi and Susumu Shiomi and Shinji Nakatani and Tadashi Takeda and Katsuhiko Fukuda and A Tamori and Daiki Habu and Takashi Tanaka},
  journal={Lancet},
  year={2001},
  volume={357 9251},
  pages={196-7}
}
In a prospective randomised controlled study, 90 patients with chronic active hepatitis C and compensated cirrhosis were assigned symptomatic treatment or interferon alfa (IFN-alpha). We report data on decompensation, detection of hepatocellular carcinoma, and mortality rates. IFN-alpha gave a sustained response in only a small proportion of patients, but worsening of compensated cirrhosis was prevented and development of hepatocellular carcinoma was inhibited, increasing the survival rate. The… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 67 extracted citations

References

Publications referenced by this paper.
Showing 1-7 of 7 references

The long - term outcomes of patients with compensated hepatitis C virusrelated cirrhosis and history of parenteral exposure in the United States

  • Hu K-Q, MJ Tong
  • Lancet
  • 1995

Avaliação do efeito protetor de vacina polissacarídica antimeningocócica do grupo C , em crianças de 6 a 36 meses

  • Galvao PAA, JS Morais
  • Rev Inst Adolfo Lutz
  • 1978

Similar Papers

Loading similar papers…